Grocery Retailers See 3.8% Incremental Sales Growth With New Data-Driven Business Model
5.6.2025 08:30:00 CEST | Business Wire | Press Release
Grocery retailers using L’s tactical loyalty campaigns have seen an average 3.8% like-for-like sales growth*, even as rising costs, global trade tensions and inflation put additional pressure on already thin margins. With tariffs and supply chain disruptions pushing up consumer prices, shoppers are prioritising value more than ever.
"Retailers are navigating a perfect storm of rising costs and uncertain consumer behaviours," says Patrik Sundvisson, CEO of L - founders of loyalty. "With Total Store Impact, we go beyond building campaigns – we're offering a proven, data-driven approach to growing sales today and building brand equity for tomorrow."
This shift comes at a critical time. As consumer spending habits turn toward value-driven purchasing, retailers must rethink their promotional strategies to differentiate their offerings and protect their bottom line.
Data-Driven Tactical Loyalty: A Smarter Approach to Retail Growth
L’s new data-driven model, Total Store Impact, strategically integrates tactical loyalty campaigns into the retailer's marketing mix, creating a continuous cycle of value for customers and growth for retailers. By incentivising visits through free rewards, shoppers are encouraged to return more frequently and spend more per trip. This short-term boost enables retailers to generate immediate revenue and reinvest in their operations, fuelling a positive productivity loop.
What sets L’s approach apart?
- Immediate Business Gains: Retailers implementing L’s model have seen 3.8% average like-for-like sales growth – a significant impact on revenue and profitability.
- Sustained Brand Growth: By embedding emotional connection, brand alignment and sustained engagement strategies, retailers strengthen their long-term brand equity and reputation, ensuring sustainable growth.
- AI & Consumer Insights: By leveraging predictive analytics, L forecasts customer behaviour and optimises operations for retailers, ensuring seamless execution.
A Global View from the Centre of Retail
As the strategic partner for the world’s leading retailers for more than 30 years, L brings unique insight into the challenges shaping the industry.
“Every retailer I speak with – whether in Europe, North America or Asia – faces the same challenge: how do we protect margins while continuing to engage customers meaningfully?” says Sundvisson. “The reality is that traditional promotions are no longer enough. Retailers need a data-driven, total-store strategy that enhances storewide performance, differentiates their brand and keeps customers coming back more often.”
With a newly launched website and an upcoming presence at the Consumer Goods Forum (CGF), L is doubling down on its mission to help retailers thrive. Visit www.L-founders.com to learn more.
Method:
Sales growth based on analysis of 43 campaigns across 28 retailers in 13 markets. Final numbers may vary per region.
About L - founders of loyalty
L - founders of loyalty is the global leader in tactical loyalty campaigns for grocery retailers. With over 30 years of experience across 35 markets and five continents, L partners with 100+ leading grocery retailers, representing nearly €500B in annual sales and engaging over 60M customers worldwide.
At the core of their approach is Total Store Impact – a data-driven business model designed to optimise customer spending across the entire store assortment. By integrating behavioural insights, AI-driven analytics and precision-targeted incentives, L’s campaigns boost sales productivity and improve profit margins in the short term, while strengthening brand equity and long-term business growth.
For more details, visit www.L-founders.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604757596/en/
Contacts
Press Contact
Mishka Noonan, L - founders of loyalty
Email: mishka.noonan@l-founders.com
Stephanie Manning, Ikigai Communications
Email: stephanie.manning@l-founders.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom